Coagulation and hemorrhage in the critically-ill patient. Part II. Prognostic factor and treatment;Coagulación y hemorragia en el paciente crítico. Parte II. Factor pronóstico y tratamiento

Medicina Intensiva

Volumn 27, Issue 10, 2003, Pages 676-685

  Quintana Diaz M ^a   Cabestrero Alonso, D ^b   Garcia De Lorenzo Y Mateos A ^c  

^a HOSPITAL NUESTRA SEÑORA DEL PRADO   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Coagulation; Critically ill patients; Disseminated intravascular coagulation; Hemorrhage; Prognostic index; Prohemostatic drugs

Indexed keywords

HEMOSTATIC AGENT;

BLEEDING; BLOOD CLOTTING; BLOOD TRANSFUSION; CENTRAL NERVOUS SYSTEM; CRITICAL ILLNESS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ACTIVITY; ENDOSCOPIC THERAPY; HUMAN; HYPOVOLEMIC SHOCK; INTENSIVE CARE; MORBIDITY; MORTALITY; PROGNOSIS; REVIEW;

EID: 1142286626     PISSN: 02105691     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0210-5691(03)79992-6     Document Type: Review

References (90)

1. García de Lorenzo A, López J, Sánchez M. Respuesta inflamatoria sistémica: fisiopatología y mediadores. Med Intensiva. 2000;24:361-70.
2. Paparella D, Luca Tupputi L. Management of coagulative disorders in the critically ill. Intensive Care Med 2000;26:1863-6.
3. Levi M, Vink R, de Jonge E. Pro-hemostatic therapy for prevention and treatment of bleeding. En: Vincent JL, editor. Springer Verlag Yearbook of Intensive Care and Emergency Medicine 2002:649-60.
4. Johnson JW, Gracias VH, Schwab CW, Reilly PM, Kauder DR, Shapiro MB, et al. Evolution in damage control for exsanguinating penetrating abdominal injury. J Trauma 2001;51:261-9.
5. Alvarez M, Nava JM, Rue M, Quintana S. Mortality prediction in head trauma patients. Performance of Glasgow Coma Score and general severity systems. Crit Care Med 1998;26:142-8.
6. Bell RC, Coalson JJ, Smith JD, Johanson WG. Multiple organ system failure and infection in adult respiratory distress syndrome. Ann Intern Med 1983;99:293-8.
7. Henao FJ, Daes JE, Dennis RJ. Risk factors of multiorgan failure: a case-control study. Trauma 1991;31:74-80.
8. Knaus WA, Draper EA, Wagner DP, Zimmermann JE. APACHE II: a severity of disease clasification system. Crit Care Med 1985;13:818-29.
9. Goris RJA, Boekhurts TPA, Nuytinck JKS, Gimbrere JSF. Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg 1985;120:1109-15.
10. Marshall JC, Christou NV, Horn H, Meakins JL. The microbiology of multiple organ failure. The proximal GI tract as an occult reservoir of pathogens. Arch Surg 1988;123:309-15.
11. Marshall JC, Cook DJ, Sibbald WJ, Roy PD, Christou NV. The multiple organ dysfunction (MOD) score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1992;20: S80.
12. Chiu P, Roy PD, Marshall JC. Blood transfusion is a risk factor for ICU-adquired infection and the multiple organ dysfunction syndrome (MODS). Crit Care Med 1993;21:S126.
13. 1, Study Group. Adult respiratory distress syndrome. Sequence and importance of developement of multiple organ failure. Chest 1992;101:320-6.
14. Border JR, Chernier R, McMenamy RH, La Duca J. Multiple systems organ failure: muscle fuel deficit with visceral protein malnutricion. Surg Clin North Am 1976;56:1147-67.
15. Carrico CJ, Meakins JL, Marshall JC, Fry D, Maier RV. Multiple organ failure syndrome. Arch Surg 1986;121:196-208.
16. De Camp MM, Demling RH. Postraumatic multisystem organ failure. JAMA 1988;260:530-4.
17. Deitch EA. Multiple organ failure. Pathophysiology and potencial future therapy. Ann Surg 1992;216:117-34.
18. Faist E, Baue AE, Dittmer H, Heberer G. Multiple organ failure in polytrauma patients. J Trauma 1983;23:775-87.
19. Knaus WA, Draper EA, Wagner DP, Zimmermann JE. Prognosis in acute organ system failure. Ann Surg 1985;202:685-93.
20. Tran DD, Groeneveld ABJ, van der Meulen J. Age, chronic disease, sepsis, organ system failure and mortality in a medical intensive care unit. Crit Care Med 1990;18:474-9.
21. Vicent JL, Moreno R, Takala J, Willatts S, de Mendoza A, Bruining H, et al. The SOFA (Sepsis related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707-10.
22. Pondaag W. Disseminated intravascular coagulation related to outcome in head injury. Acta Neurochir suppl 1979;28:98-102.
23. Olson JD, Kaufman HH, Maake J. The incidence and significance of hemostatic abnormalities in patients with head injuries. Neurosurgery 1989;24:825-32.
24. Gando S, Tedo I, Kubota M. Posttrauma coagulation and fibrinolysis. Crit Care Med 1992;20:594-600.
25. Dantzker DR, Wagner PD, Tornabene VW, Alazraki NP, West JB. Gas exchange after pulmonary thromboembolization in dogs. Circ Res 1978;42:92-103.
26. Kumura E, Sato M, Fukuda A, Takemoto Y, Tanaka S, Kohama A. Coagulation disorders following acute head injury. Acta Neurochir (Wien) 1987;85:23-8.
27. Pieck J, Chesnut RM, Marshall LF, van Berkum-Clark M, Klauber MI, Blunt BA. Extracranial complications of severe head injury. J Neurosurg 1992;77:901-7.
28. Suzuki M, Motohashi O, Nishino A, Shiina V, Mizoi K, Yoshimoto T, et al. Diphasic increase in thrombin-antithrombin III complex in blood from the internal jugular vein following severe head injury. Thromb Haemost 1994;71:155-7.
29. Touho H, Hirakawa K, Hino A, Karasawa J, Ohno Y. Relatioship between abnormalities of coagulation and fibrinolysis and postoperative intracraneal hemorrhage in head injury. Neurosurgery 1986;19:523-31.
30. Kaufman HH, Moake JL, Olson JD, Miner ME, du Cret RP, Pruessner JL, et al. Delayed and rerrent intracraneal hematomas related to disseminated intravascular clotting and fibrinolysis in head injury. Neurosurgery 1980;7:447-9.
31. Asakura H, Ontachi Y, Mizutani T, Kato M, Saito M, Kumabashiri I, et al. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation. Crit Care Med 2001;29:1164-8.
32. Colvin BT. Management of disseminated intravascular coagulation. Br J Haematol 1998;101(Suppl 1):15-7.
33. Humphries JE. Transfusion therapy in acquired coagulopathies. Hematol Oncol Clin North Am 1994;8:1181-201.
34. Corrigan JJ Jr. Heparin therapy in bacterial septicemia. J Pediatr 1977;91:695-700.
35. Klein HG, Bell WR. Disseminated intravascular coagulation during heparin therapy. Ann Intern Med 1974, 80:477-81.
36. Rubin RN, Colman RW. Disseminated intravascular coagulation. Approach to treatment. Drugs 1992;44:963-71.
37. Heene DL. Blood coagulation mechanism and endotoxin: Hemostatic defect in septic shock. En: Urbascheck B, editor. Gram-Negative Bacterial Infections and Mode of Endotoxin Actions. Viena: Springer, 1975; p. 375-87.
38. Staudinger T, Locker GJ, Frass M. Management of acquired coagulation disorders in emergency and intensive-care medicine. Semin Thromb Hemost 1996;22:93-104.
39. Cabestrero D, Gálvez MA, Martín C, Cidoncha M, García de Lorenzo A. Heparinas de bajo peso molecular en pacientes críticos: usos, indicaciones y tipos. Med Intensiva 2001;251:18-26.
40. Bick RL, Fareed J. Low molecular weight heparins: differences and similarities in approved preparations in the United States. Clin Appl Thromb Hemost 1999;5(Suppl 1):S63-6.
41. National Institutes of Helth. Transfusion alert: indications for the use of red blood cells, platelets, and fresh frozen plasma. Bethesda: Dept. of Health and Human Services, 1989 Spring (Issued in dratf form by National Blood Resource Education Program Expert Panel).
42. Oberman HA. Considerations in the transfusion of plasma, plasma components and plasma derivates. En: Kolins J, McCarthy LJ, editors. Contemporary transfusion practice. Arlington: AM Assn of Blood Banks, 1997; p. 27-47.
43. Simon TL. Platelets: uses, abuses and indications. En: Kolins J, McCarthy LJ, editors. Contemporary transfusion practice. Arlington: Am Assn of Blood Banks, 1997; p. 47-63.
44. Bick RL. Platelet function defects: a clinical review. Sem Thromb Hemost 1992;18:167-85.
45. Contreras M. The apropiate use of plateletes: an update from the Edimburg Consensus Conference. Br J Haematol 1998;101(Suppl 1):10-2.
46. Levi M, van der Poll T. Hemostasis and coagulation. En: Narton JA, Bollinger RA, Chang AE, Lowry SF, editors. Surgery: Scientific Basis and current Practice. New York: Springer, 2000; p. 161-76.
47. Ayuzawa S, Matsumura A, Mitsui Y, Takeuchi S, Yoda Y, Nose T. Coagulation and fibrinolysis in head injury: An analysis with new molecular markers. En: Recent advances in neuro traumatology. Tokyo: Springer-Verlag, 1993; p. 462-5.
48. Lechner K, Kyrle PA. Antithrombin III concentrates- Are they clinically useful? Thromb Haemost 1995;73:340-8.
49. Schinzel H, Weilemann LS. Antithrombin substitution therapy. Blood Coagul Fibrinolysis 1989;9:S17-21.
50. Fourrier F, Jourdain M, Tournoys A. Clinical trial results with antitrombin III in sepsis. Crit Care Med 2000;28(Suppl 9): S38-43.
51. Diaz-Cremades JM, Lorenzo R, Sánchez M, Moreno MJ, Alsar MJ, Bosch JM, et al. Use of antithrombin III in critical patients. Intensive Care Med 1994;20:577-80.
52. Waydhas C, Nast-Kolb D, Gippner-Steppert C, Trupka A, Pfundstein C, Schweiberer L, et al. High-dose antithrombim III treatment of severely injured patients: results of a prospective study. J Trauma 1998;45:931-40.
53. Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, et al. Antitrombin III replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998;24:336-42.
54. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, et al. Antitrombin III in patients with severe sepsisa randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo controlled, double-blind trials with antitrombin III in severe sepsis. Intensive Care Med 1998;24:663-72.
55. Marder VJ, Butler FO, Barlow GH. Antifibrinolytic therapy. En: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and thrombosis: Basic principles and clinical practice. Philadelphia: Lippincott, 1994; p. 795-814.
56. Levi M, Cromheecke ME, de Jonge E, Prins MH, de Mol BJ, Briet E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999;354:1940-7.
57. Muñoz JJ, Birkmeyer NJ, Birkmeyer JD, O'Connor GT, Dacey LJ. Is epsilon-aminocaproic acid as effective as aprotonin in reducing bleeding with cardiac surgery?: a meta-analysis. Circulation 1999;99:81-99.
58. Fremes SE, Wong BI, Lee E, Mai R, Cristakis GT, McLean RF, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994;58:1580-8.
59. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: a meta-analysis using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 1997;85:1258-67.
60. Porte RJ, Molenaar IQ, Begliomini B, Groeland TH, Januszkiewicz A, Lindgren L, et al. Aprotonin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind stydy. EMSALT Study Group. Lancet 2000;355:1303-9.
61. Van der Meer J, Hillege HI, Kootstra GJ, Ascoop CA, Mulder BJ, Pfisterer M, et al. Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of the Netherlands. Lancet 1993;342:257-64.
62. Mannucci PM. Hemostatic drugs. NEJM 1998;39:245-53.
63. Mannucci PM. Desmopresin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997;90:2515-21.
64. Hedner U. Recombinant activated factor VII as a universal haemostatic agent. Blood Coagul Fibrinolysis 1998;9(S): 147-52.
65. Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 1998;9(S): 115-8.
66. Friederich PW, Wever PC, Briet E, Doorenbos CJ, Levi M. Succesful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001;66:292-4.
67. Friederich PW, Geerdink MG, Spataro M, Messelink EJ, Henry CP, Buller HR, et al. The effect of the administration of recombinant activated factor VII (NovoSeven) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Blood Coagul Fibrinolysis 2000;11(S):129-32.
68. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003;361:201-5.
69. Erhardtsen E. Ongoing NovoSeven trials. Intensive Care Med 2002;28(S):248-55.
70. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001;51:431-8.
71. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999;354:1879.
72. O'Neil PA, Bluth M, Gloster ES, Wali D, Priovolos S, Di-Maio TM, et al. Succesful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma 2002;52:400-5.
73. Lynn M, Jeroukhimov I, Klein Y, Martinowitz U. Updates in the management of severe coagulophaty in trauma patients. Intensive Care Med 2002;28(S):241-7.
74. Saldeen T. Clotting, microembolism, and inhibition of fibrinolysis in adult respiratory distress. Surg Clin North Am 1983;63:285-304.
75. Boldt J, Müller M, Heesen M, Heyn S, Hempelmann G. Dose long-term continuous administration of pentoxifylline affect platelet function in the critically ill patients? Intensive Care Med 1996;22:644-50.
76. Carrasco M, Fontcuberta J, Argilés B, Mateo J. Alteración de la hemostasia en el paciente politraumatizado. En: Net A, Marruecos L, editors. El paciente politraumatizado. Barcelona: Springer, 2001; p. 80-90.
77. Atkins PJ. Postoperative coagulopathies. Crit Care Nurs Clin North Am 1993;5:459-73.
78. Hesselvik JF, Malm J, Dahlback B, Blomback M. Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 1991;65:126-9.
79. Vicent JL. Microvascular endothelial dysfunction: A renewed appreciation of sepsis pathophysiology. Crit Care Med 2001;5:S1-5.
80. Bernard GR, Vincent JL, Laterre PF, la Rosa SP, Dhainaut JF, López Rodríguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:669-709.
81. Angus DC, Vicent JL, Artigas A. The effect of recombinant human Activated Protein C (rhAPC) on organ dysfunction and funcyional recovery in severe sepsis. Crit Care Med 2000;28:A48.
82. Hermida J, Rocha E. Papel fisiopatológico del sistema de la proteína C en la CID y sus posibles implicaciones terapéuticas. Rev Iberoamer Tromb Hemostasia 2000;13(Supl 1):99-115.
83. Ely EW, la Rosa SP, Bernard GR. Effect of age effect on mortality reduction associated with recombinant human activated protein C in patients with severe sepsis. Am J Resp Crit Care Med 2002;163(Suppl):A459.
84. Maruyama I. Recombinant thrombomodulin activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999;82:718-21.
85. Colman RW, Flores DN, de la Cadena RA, Scott CF, Cousens L, Barr PJ, et al. Recombinant-antitrypsin Pittsburg attenuates experimental Gram-negative septicemia. Am J Pathol 1988;130:418-26.
86. Walenga JM, Hoppensteadt A, Koza M, Pifarre R, Fareed J. Comparative studies on varius assays for the laboratory evaluation of r-hirudin. Semin Thromb Hemost 1991;17:103-12.
87. Vedder NB, Winn RK, Rice CL, Chi EY, Arfors KE, Harlam JM. A monoclonal antibody to the adherence-promoting leukocyte glycoprotein, CD18, reduces organ injury and improves survival from hemorragic shock and resuscitation in rabbits. J Clin Invest 1988;81:939-44.
88. Nakano H, Kuzume M, Namatame K, Yamaquchi M, Kumada K. Efficacy of intraportal injection of anti-ICAM-1 monoclonal antibody against liver cell injury following warm ischemia in the rat. Am J Surg 1995;170:64-6.
89. Nolte D, Hecht R, Schmid P, Botzlar A, Menger MD, Neumueller C, et al. Role of Mac-1 and ICAM-1 in ischemia-reperfusion injury in a microcirculation model of BALB/C-mice. Am J Physiol 1994;267:1320-8.
90. Vollmar B, Glasz J, Menger MD, Messmer K. Leukocytes contribute to hepatic ischemia-reperfusion injury via intercellular adhesion molecule-1-mediated venular adherence. Surgery 1995;117:195-200.